Venning V A, Wojnarowska F
Department of Dermatology, Slade Hospital, Oxford, United Kingdom.
J Am Acad Dermatol. 1992 Apr;26(4):585-9. doi: 10.1016/0190-9622(92)70085-t.
Bullous pemphigoid is a clinically heterogeneous disease although little is known of the factors affecting its course and outcome.
Our purpose was to document the clinical course, outcomes, and causes of death in treated bullous pemphigoid and to determine the predictive factors affecting outcome.
The clinical course was documented in 82 patients with immunologically proven bullous pemphigoid (mean follow-up 3 years 2 months). To identify factors predictive of outcome, 16 patients with "good prognosis bullous pemphigoid" (no systemic treatment or in remission within 2 years) were compared with 12 patients with recurrent disease requiring maintenance therapy who still needed treatment after 3 years or longer. Remission was defined as 3 months free of lesions, without systemic treatment.
The disease duration varied from 9 weeks to 17 years (estimated median treatment time 2 years 1 month). Of patients followed up for at least 2 years, 30% achieved remission and by 3 years the remission rate was 50%. Two patients had a subsequent relapse (9%). The mortality rate at 1 year was 19%, and treatment was believed to be contributory in seven deaths. No clinical, immunologic, or immunogenetic factors were predictive of disease duration.
Despite the heterogeneity of the clinical course and duration of bullous pemphigoid, no predictive factors are recognized.
大疱性类天疱疮是一种临床异质性疾病,尽管对影响其病程和转归的因素了解甚少。
我们的目的是记录接受治疗的大疱性类天疱疮的临床病程、转归及死亡原因,并确定影响转归的预测因素。
记录了82例经免疫学证实的大疱性类天疱疮患者的临床病程(平均随访3年2个月)。为确定转归的预测因素,将16例“预后良好的大疱性类天疱疮”患者(未接受全身治疗或在2年内缓解)与12例复发疾病需要维持治疗且3年或更长时间后仍需治疗的患者进行比较。缓解定义为无皮损3个月且未接受全身治疗。
病程从9周至17年不等(估计中位治疗时间为2年1个月)。随访至少2年的患者中,30%实现缓解,到3年时缓解率为50%。2例患者随后复发(9%)。1年时死亡率为19%,据信7例死亡与治疗有关。没有临床、免疫或免疫遗传学因素可预测病程。
尽管大疱性类天疱疮的临床病程和持续时间存在异质性,但尚未发现预测因素。